Company type | Public |
---|---|
Nasdaq: ME | |
Industry | |
Founded | April 2006 |
Founders |
|
Headquarters | , United States |
Key people | |
Products | |
Services | |
Revenue | US$192 million (2024) |
US$−681 million (2024) | |
US$−666 million (2024) | |
Total assets | US$395 million (2024) |
Total equity | US$189 million (2024) |
Number of employees | 582 (2024) |
Website | 23andme |
Footnotes / references Financials as of March 31, 2024[update].[1] |
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California.[1][2] It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping,[3] to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.[4]
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use.[5] Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.[6][7]
The company had a previously fraught relationship with the United States Food and Drug Administration (FDA) due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval.[8][9] 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014,[10][11][12] and in the UK since December 2014.[13]
23andMe became a publicly traded company in 2021 and soon had a market capitalization of US$6 billion.[14] By 2024, its valuation had fallen to 2% of that peak.[14] On September 17, 2024, all seven independent directors of the company resigned.[15]
Wired2007
was invoked but never defined (see the help page).Time
was invoked but never defined (see the help page).